Weight: Coren's first inhaler is here! The 20 billion market is heating up rapidly

On January 28th, Colum's declaration of a class 4 imitation of the inhaled isopropyl tobly bromide solution was approved by CDE, the company's first inhaler, which attracted market attention.
meters intranet data show that in China's public medical institutions terminal, the market size of inhalers in 2018 has exceeded 20 billion yuan, 2018-2019 growth rate of more than 10%, the first half of 2020 affected by the epidemic growth rate declined.
Figure 1: Registration of isopropyl bromide solution for inhalation by Hunan Colum Pharmaceuticals Source: CDE Official Website Figure 2: Sales of isopropyl tobly bromide solution for inhalation Source: Isopropyl tobly bromide For anti-ammonium for terminal competition in China's public medical institutions Choline-energy drugs, with strong bronchial smooth muscle relaxation, can significantly improve lung function and exercise tolerance in patients with chronic obstructive pulmonary disease (COPD), relieve the symptoms of respiratory difficulties, improve sleep and quality of life, is one of the main drugs to treat COPD.
research products developed by Grigg Ingham, entered the domestic market in 2004, is the national health insurance catalog Class A varieties.
meters intranet data show that in the first half of 2020 in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) terminal inhaler TOP20 products, inhalation of isopropyl tobly bromide solution ranked ninth, the product has grown to more than 1 billion products from 2018. table
1: The current review of isopropyl tobly bromide inhalants involved in the enterprise situation Source: Minet MED2.0 China Drug Review Database At present, the product by the original pharmaceutical companies leading the market, the first half of 2020 market share is still more than 90%.
In 2020, the four generics of Shenzhen Mrs. Pharmaceuticals and Four Trump Rite Pharmaceuticals were approved and evaluated as such, and there are currently seven applications for the listing of isopropyl toblyblycide-related inhalants.
By virtue of Colum's strength, after successful approval is expected to become a strong competitor to the original research products, the beginning of 2021 is not more than a month, Colum has seven high-end generic drugs declared on the market and in the review and approval, the next two to three years will also be the big infusion leader new products approved blowout period.